Product Information
ENTECAVIR 0.5 MG TABLET is a generic product labeled by Cameron Pharmaceuticals, priced at $0.2186 per EA under NDC 42494045730. Its NADAC has been published 58 times since Aug 27, 2025.
FDA first approved this application on Dec 23, 2024. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
.5 mg/1
Manufacturer
Cameron PharmaceuticalsNDC
42494045730
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ENTECAVIR ANHYDROUSApproval Type
Generic (ANDA)
FDA Application
ANDA216857FDA Approved
12/23/2024
TE Code
AB
On Market Since
5/15/2025
Pharmacological Classes
Price Statistics
The NADAC for ENTECAVIR 0.5 MG TABLET has been published 58 times since Aug 27, 2025, and over the history we have for it it has declined 16.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2186 per EA |
|---|---|
| All-time high | $0.2640 (Oct 15, 2025) |
| All-time low | $0.2096 (May 20, 2026) |
| 52-week high | $0.2640 |
| 52-week low | $0.2096 |
| Median price | $0.2213 |
| Average price | $0.2271 |
| Largest weekly change | -8.5% (Oct 22, 2025) |
| Weeks tracked | 58 |
| Tracking since | Aug 27, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the ENTECAVIR ANHYDROUS market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Cameron Pharmaceuticals manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ENTECAVIR ANHYDROUS market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ENTECAVIR 0.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ENTECAVIR 0.5 MG TABLET, manufactured by Cameron Pharmaceuticals, is $0.2186 per EA (NDC 42494045730), effective Sep 30, 2026.
How has the price of ENTECAVIR 0.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for ENTECAVIR 0.5 MG TABLET has declined 16.7%. It has been tracked across 58 weekly CMS publications since Aug 27, 2025.
What are the highest and lowest recorded NADAC prices for ENTECAVIR 0.5 MG TABLET?
Since Aug 27, 2025, the NADAC for ENTECAVIR 0.5 MG TABLET has ranged from a low of $0.2096 (May 20, 2026) to a high of $0.2640 (Oct 15, 2025), with a median of $0.2213 per EA.
Are there cheaper alternatives to ENTECAVIR 0.5 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of ENTECAVIR 0.5 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ENTECAVIR 0.5 MG TABLET?
ENTECAVIR 0.5 MG TABLET (NDC 42494045730) is labeled by Cameron Pharmaceuticals, and CMS classifies it as a generic product.